



## ***Ryan J. Gunderson***

**PARTNER**

**San Diego**

P +1 858 436 8046

Ryan provides strategic advice to founders, investors, management teams, and boards of directors as they grow their businesses and execute their business plans.

Ryan advises clients in the life sciences and technology industries. Ryan serves as his clients' primary outside counsel, providing strategic advice and corporate counseling to founders, management teams, boards of directors, and venture funds. He enjoys helping his clients raise capital to develop their products and technologies, acquire new technologies and products, and grow and expand their businesses through venture financings and public offerings. Ryan is recognized by his clients for providing practical legal and business advice and his extensive deal experience and industry knowledge. Over the course of his career, Ryan has represented companies in some of their most complex and consequential transactions, including life sciences companies (biotechnology, pharmaceuticals, medical devices, tools, and services) and technology companies in the AI, ecommerce, software, media, and networking industries.

Ryan has extensive experience with startup and formation matters and venture capital financings, mergers and acquisitions, and other complex transactions. Ryan also has extensive industry-leading experience in initial public offerings, and other equity and debt capital markets transactions (including follow-on offerings, ATMs, PIPEs, 144A offerings, and registered directs). He also represents various public companies in ongoing SEC compliance, corporate governance matters, and capital raising.

Ryan has guided many of his clients through the entire life cycle, from formation through multiple venture financings, initial public offerings, and exits. He also regularly represents leading venture capital funds in their investments and other portfolio matters.

Ryan enjoys being outdoors with his family; riding motorcycles and horses, boating, mountain biking, or taking care of their myriad animals.

## Credentials

### EDUCATION

- University of San Diego School of Law, J.D.
- Brigham Young University, B.S., Finance

### BAR ADMISSIONS

- California

## Focus Areas

Corporate Governance & Strategy

Fund Investments in Companies

Initial Public Offerings (IPOs) & Direct Listings

Life Sciences

Mergers & Acquisitions

Public Companies/Public Offerings

Seed, Venture and Growth Financings

# What to Know About Crossover Rounds as a Late-Stage Private Company

Gunderson Dettmer partners Ryan Gunderson and Jeff Thacker hosted a discussion on the benefits and considerations of raising capital from crossover funds as part of an IPO Summit series of workshops. The panel provided an overview of the benefits of raising capital from crossover funds from both the company and the investor perspective, as well as discussed practical considerations when choosing investors for any crossover.

## Related News & Insights

### CLIENT NEWS

9 Gunderson Dettmer Clients Are Finalists in EY's 2024 Entrepreneur of the Year Awards

### CLIENT NEWS

Tarsus Pharmaceuticals Announces \$200M Committed Capital from Pharmakon Advisors

### CLIENT NEWS

Foresite Capital Participates in Cullinan Therapeutics \$280M Stock Purchase Agreement

### CLIENT NEWS

Contineum Therapeutics Announces Initial Public Offering

### CLIENT NEWS

S32 Leads \$33M Series C Financing of Brightside Health

### CLIENT NEWS

Gunderson Dettmer Advises Tarsus Pharmaceuticals On \$115.0 Million Public Offering

### CLIENT NEWS

Veradigm Acquires ScienceIO for \$140M

## INSIGHTS

### S32 Co-Leads the \$30M Financing of Puzzle

## CLIENT NEWS

### Cell-Free DNA Testing Company Natera Announces \$250M Follow-On Offering

## CLIENT NEWS

### Tarsus Pharmaceuticals Announces \$100M Public Offering

## EVENTS

### Webinar: What to Know About Crossover Funds as a Late-Stage Company

## CLIENT NEWS

### Section 32 Leads \$75M Series B Financing of BigHat Biosciences to Design Safer, More Effective Antibodies

## CLIENT NEWS

### Tarsus Pharmaceuticals Announces Upsized Underwritten Public Offering